Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Botanix Pharmaceuticals Limited has issued over 3.4 million new shares, which are now available for immediate trading, following the exercise of equivalent unquoted options. The company, a pioneer in dermatological treatments, recently received FDA approval for Sofdra™, a novel product for primary axillary hyperhidrosis, and is advancing a pipeline of late-stage clinical products for various skin conditions.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.